A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery
Open Access
- 21 May 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (21) , eabf0197
Abstract
Potential combination partners of a CDC7 inhibitor TAK-931 were identified to guide its clinical development strategy.Keywords
Funding Information
- Takeda Science Foundation
- the Grants-in-Aid for Scientific Research (20H03541)
- The Grants-in-Aid for Fostering Joint International Research (20KK0187)
- Takeda Pharmaceutical Company, Ltd
This publication has 45 references indexed in Scilit:
- Clonal Heterogeneity and Tumor Evolution: Past, Present, and the FutureCell, 2017
- Increased global transcription activity as a mechanism of replication stress in cancerNature Communications, 2016
- Exploiting replicative stress to treat cancerNature Reviews Drug Discovery, 2015
- Causes and consequences of replication stressNature Cell Biology, 2013
- The causes and consequences of genetic heterogeneity in cancer evolutionNature, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The DNA-damage response in human biology and diseaseNature, 2009
- An Oncogene-Induced DNA Damage Model for Cancer DevelopmentScience, 2008
- Activation of the DNA damage checkpoint and genomic instability in human precancerous lesionsNature, 2005
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005